急性呼吸障害症候群における吸入鎮静:SESARランダム化臨床試験
Matthieu Jabaudon1,2, Jean-Pierre Quenot3, Julio Badie4
1Department of Perioperative Medicine, CHU Clermont-Ferrand, Clermont-Ferrand, France.
JAMA
|March 18, 2025
まとめ
急性呼吸困難症候群 (ARDS) の患者に対する吸入セボフルーラン鎮静剤は,静脈注射プロポフォールと比較して,呼吸器なしで過ごす日数が少なく,90日間の生存率が低かった. この研究では,ARDSの管理におけるセボフルランの潜在的なリスクが強調されています.
科学分野:
- クリティカル ケア 医療
- 呼吸器医学
- 麻酔科
背景:
- 急性呼吸困難症候群 (ARDS) を有する機械的に呼吸する成人のための最適な鎮静策は不明である.
- 静脈内静止と吸入による静止薬の差異的な効果を研究することは,ARDS患者のアウトカムに極めて重要です.
研究 の 目的:
- ARDSと診断された患者における静脈内プロポフォールの効果と安全性を比較する.
- ARDSの主要な臨床結果に対する異なる鎮静法の影響を評価する.
主な方法:
- 中等から重度のARDSの687人の成人を対象とした,ランダム化,オープン・ラベル,盲検臨床試験.
- 患者は最大7日間,セボフルーランを吸入またはプロポフォルを静脈内投与した.
- 主要エンドポイント: 28日目の呼吸器のない日; 主要な二次エンドポイント: 90日生存率.
主要な成果:
- 吸入セボフルーランは,プロポフールと比較して28日目に呼吸器なしで過ごす日数が少なくなった (中位差: - 2. 1日).
- 90日生存率はプロポフォール (55. 7%) と比較してセボフルーラン (47. 1%) よりも低かった.
- セボフルランは7日間の死亡率も高く,ICUのいない日は少なくなった.
結論:
- 中度から重度のARDS患者におけるセボフルランによる吸入鎮静剤は,静脈内プロポフォールより悪い結果をもたらした.
- これらの発見は,プロポフォルがARDS患者にとってより安全で効果的な鎮静剤の選択である可能性があることを示唆しています.
- この集団におけるセボフルーランの使用をさらに研究し,代替の吸入剤を探求することができる.
さらに関連する動画
関連する概念動画
Inhalational Anesthetics: Overview
964
Inhalation anesthetics are drugs that induce general anesthesia upon inhalation. They work by increasing the sensitivity of GABAA receptors or inhibiting NMDA receptors, leading to a decrease in central nervous system activity. The depth of anesthesia can be rapidly adjusted by changing the concentration of the inhaled gas. Some common examples of inhalational anesthetics include volatile liquids like isoflurane, desflurane, sevoflurane and gases like xenon and nitrous oxide. Isoflurane, a...
964
Stages of General Anesthesia
1.4K
Various sedation levels offer significant advantages in facilitating procedural interventions for patients undergoing medical or invasive surgical procedures. These levels span from anxiolysis to general anesthesia, providing a spectrum of sedative effects to cater to specific patient needs. Anxiolysis reduces anxiety and is achieved through minimal sedation, enabling patients to remain awake and responsive while feeling more at ease during the procedure. This level can benefit minor...
1.4K
Acute Respiratory Failure-IV
494
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
494
Parenteral Anesthetics: Overview
554
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
554
Sedatives and Hypnotics: Overview
1.3K
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
1.3K
Acute Respiratory Failure-II
992
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
992


